Shares of Novavax Inc.
NVAX,
were up 2.4% in premarket trading on Friday after the company said its COVID-19 booster was authorized for adults in Canada who were previously immunized with Novavax’s protein-based vaccine. The company’s stock is down 85.4% this year, while the S&P 500
SPX,
has declined 17.2%.
